Evidence map›Paper›PMID 25301857›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2014

Self-rated health and adverse events in CKD.

Cassianne Robinson-Cohen, Yoshio N Hall, Ronit Katz, Matthew B Rivara, Ian H de Boer, Bryan R Kestenbaum, Jonathan Himmelfarb

Abstract readComparative Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Reliability and Utility of the Surprise Question in CKD Stages 4 to 5.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017
    Observational
  14. Observational
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Cassianne Robinson-CohenKidney Research Institute, Department of Epidemiology, and cassyrc@uw.edu.
Yoshio N HallKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Ronit KatzKidney Research Institute.
Matthew B RivaraKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Ian H de BoerKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Bryan R KestenbaumKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Jonathan HimmelfarbKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
University of Washington · USKidney Research UK · GB

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Julie Mathieu · 1986 to 2026
$41.4M
RESEARCH TRAINING IN RENAL DISEASET32DK007467 · NIDDK · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA, KESTENBAUM, BRYAN R · 1986 to 2023
$5.1M
Oxidative Stress in Chronic Kidney DiseaseR01HL070938 · NHLBI · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN, IKIZLER, TALAT ALP · 2003 to 2012
$3.2M
NHLBI NIH HHS 2R01-HL070938NHLBI NIH HHS R01 HL070938NIDDK NIH HHS P30 DK017047NIDDK NIH HHS T32 DK007467
6 · The paper itself

Abstract

BACKGROUND AND

objectivesLittle is known about the utility of self-rated general health assessments in persons with moderate-to-severe CKD. This study examined the ability of a single self-rated health measure to predict all-cause mortality and kidney disease progression in a cohort of 443 patients with stages 3-4 CKD, recruited between 2005 and 2011, and followed until the end of 2012. The performance of models incorporating self-rated health measures was compared with previously published predictive models and more complex models comprising a multibiomarker panel. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants were asked "In general, would you say your health is excellent, very good, good, fair, or poor?" Outcomes examined were time to all-cause mortality, kidney disease progression (initiation of RRT or 30% loss of eGFR), and a composite of these events. Model performances were compared using a nonparametric area under the curve (AUC) analysis.

resultsOver a median follow-up of 3.3 years, 118 (27%) participants died and 138 (31%) had progression of kidney disease. Fair-to-poor self-rated health status was associated with significantly greater risks of mortality (fully adjusted hazard ratio [HR] for relative to good-to-excellent self-rated health, 2.76; 95% confidence interval [95% CI], 1.28 to 5.89), kidney disease progression (HR, 1.94; 95% CI, 1.49 to 2.56), and the combined end point (HR, 2.21; 95% CI, 1.66 to 2.96). For 3-year mortality prediction, the self-rated health model (AUC, 0.80; 95% CI, 0.76 to 0.85) had significantly higher AUCs than the base model (AUC, 0.71; 95% CI, 0.66 to 0.76) and the multibiomarker panel model (AUC, 0.74; 95% CI, 0.68 to 0.80) (P=0.03 and P=0.04, respectively).

conclusionsA single, easily obtained measure of self-rated health helps identify patients with CKD at high risk of mortality and kidney disease progression. Routine evaluation of self-rated health may help target individuals who might benefit from more intensive monitoring strategies.

Indexed as

Disease ProgressionHealth StatusAcid-Base EquilibriumAgedAlbuminuriaArea Under CurveBiomarkersCause of DeathC-Reactive ProteinCreatinineCystatin CFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesGlomerular Filtration Barrier25-hydroxyvitamin DBiomarkersC-Reactive ProteinCreatinineCystatin CFibroblast Growth Factor-23Fibroblast Growth FactorsHemoglobinsParathyroid HormoneUric AcidVitamin DCKDclinical epidemiologyESRDmortality riskprogression of chronic renal failure

Identifiers

PMID25301857
PMCPMC4255401
OpenAlexW2148630608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.